Neurometabolic Disorders Market to 2017 - Novel Therapies for Rare Diseases such as Gaucher's and Niemann-Pick Poised to Supersede Existing Therapies
NEW YORK, March 28, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Neurometabolic Disorders Market to 2017 - Novel Therapies for Rare Diseases such as Gaucher's and Niemann-Pick Poised to Supersede Existing Therapies
Summary
GBI Research has released its latest research, "Neurometabolic Disorders Market to 2017 - Novel Therapies for Rare Diseases such as Gaucher's and Niemann-Pick Poised to Supersede Existing Therapies" which provides insights into global neurometabolic disorders market and market forecast until 2017. Report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. The report provides an in-depth analysis of the Gaucher Disease Type 1, Niemann Pick Type C, Fabry Disease, Pompe Disease and Mucopolysaccharidosis VI Disease. The report examines the treatment usage patterns and also includes insights into the R&D product pipeline and explores the competitive landscape including major players in neurometabolic disorders market. Finally, the report also includes analysis on Mergers and Acquisitions (M&As) and licensing agreements that took place in neurometabolic disorders market.
Scope
- The report analyzes market characterization, pipeline analysis and key M&A trends in the Gaucher Disease Type 1, Niemann Pick Type C, Fabry Disease, Pompe Disease and Mucopolysaccharidosis VI Disease markets in the neurometabolic disorders market.
- Data and analysis on the contraceptives market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.
- Annualized market data for the Gaucher Disease Type 1, Niemann Pick Type C, Fabry Disease, Pompe Disease and Mucopolysaccharidosis VI Disease in the neurometabolic disorders market from 2002 to 2010, with forecasts to 2017.
- Market data on the therapeutic landscape which covers market revenues, treatment usage patterns and annual cost of therapy.
- Key drivers and restraints that have had a significant impact on the market
- The competitive landscape of the neurometabolic disorders market.
- Key M&A activities and Licensing Agreements that took place from 2005 to 2011 in the contraceptives market.
Reasons to buy
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the potential region and therapeutic segments poised for strong growth.
- Device a more tailored country strategy through the understanding of key drivers and barriers of the neurometabolic disorders market.
- Develop key strategic initiatives by understanding the key focus areas of leading companies.
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 10
2 Neurometabolic Disorders Market to 2017 - Introduction 12
2.1 GBI Research Report Guidance 13
3 Neurometabolic Disorders Market to 2017 - Global Market Overview 14
3.1 Introduction 14
3.2 Market Revenue 14
3.3 Annual Cost of Therapy 16
3.3.1 Treatment Usage Pattern 17
4 Neurometabolic Disorders Market to 2017 - Geographical Landscape 20
4.1 The US 21
4.1.1 Revenue 21
4.1.2 Annual Cost of Therapy 23
4.1.3 Treatment Usage Pattern 24
4.2 Top Five Countries of Europe 26
4.2.1 Revenue 26
4.2.2 Annual Cost of Therapy 28
4.2.3 Treatment Usage Pattern 29
4.3 Japan 31
4.3.1 Revenue 31
4.3.2 Annual Cost of Therapy 32
4.3.3 Treatment Usage Pattern 33
5 Neurometabolic Disorders Market to 2017 - Therapeutic Landscape 35
5.1 Neurometabolic Disorders Market to 2017 - Gaucher's Disease 35
5.1.1 Introduction 35
5.1.2 Revenue 36
5.1.3 Revenue by Geography 38
5.1.4 Annual Cost of Therapy 40
5.1.5 Treatment Usage Pattern 41
5.1.6 Treatment Algorithm 43
5.1.7 Gaucher's Type 1 Disease Therapeutics Market Drivers 44
5.1.8 Gaucher's Type 1 Disease Therapeutics Market Restraints 45
5.2 Neurometabolic Disorders Market to 2017 - Niemann-Pick Type C Disease 45
5.2.1 Introduction 45
5.2.2 Revenue 47
5.2.3 Revenue by Geography 48
5.2.4 Annual Cost of Therapy 50
5.2.5 Treatment Usage Pattern 51
5.2.6 Treatment Algorithm 53
5.2.7 Niemann-Pick Type C Market Drivers 54
5.2.8 Niemann-Pick Type C Market Restraints 55
5.3 Neurometabolic Disorders Market to 2017 - Pompe Disease 56
5.3.1 Introduction 56
5.3.2 Revenue 56
5.3.3 Revenue by Geography 58
5.3.4 Annual Cost of Therapy 60
5.3.5 Treatment Usage Pattern 61
5.3.6 Treatment Algorithm 63
5.3.7 Pompe Disease Therapeutics Market Drivers 64
5.3.8 Pompe Disease Therapeutics Market Restraints 65
5.4 Neurometabolic Disorders Market to 2017 - Fabry Disease 65
5.4.1 Introduction 65
5.4.2 Revenue 65
5.4.3 Revenue by Geography 67
5.4.4 Annual Cost of Therapy 69
5.4.5 Treatment Usage Pattern 70
5.4.6 Fabry Disease Therapeutics Market Drivers 72
5.4.7 Fabry Disease Therapeutics Market Restraints 73
5.5 Neurometabolic Disorders Market to 2017 - Mucopolysaccharidosis VI 73
5.5.1 Introduction 73
5.5.2 Revenue 74
5.5.3 Revenue by Geography 75
5.5.4 Annual Cost of Therapy 76
5.5.5 Treatment Usage Pattern 77
5.5.6 Treatment Algorithm 79
5.5.7 Mucopolysaccharidosis VI Therapeutics Market Drivers 80
5.5.8 Mucopolysaccharidosis VI Therapeutics Market Restraints 81
6 Neurometabolic Disorders Market to 2017 - Major Marketed Products 82
6.1 Gaucher's Disease 82
6.1.1 Cerezyme 82
6.1.2 VPRIV 83
6.2 Gaucher's Disease and Niemann-Pick Type C 85
6.2.1 Zavesca 85
6.3 Pompe Disease 86
6.3.1 Myozyme/Lumizyme 86
6.4 Fabry Disease 88
6.4.1 Fabrazyme 88
6.4.2 Replagal 89
6.5 Mucopolysaccharidosis VI 91
6.5.1 Naglazyme 91
7 Neurometabolic Disorders Market to 2017 - Product Pipeline Analysis 92
7.1 Gaucher's Disease - Research and Development Pipeline 94
7.1.1 Overview 94
7.1.2 Pipeline by Phase 94
7.2 Niemann-Pick Type C: Research and Development Pipeline 95
7.2.1 Overview 95
7.2.2 Pipeline by Phase 95
7.3 Pompe Disease: Research and Development Pipeline 96
7.3.1 Overview 96
7.3.2 Pipeline by Phase 96
7.4 Fabry Disease: Research and Development Pipeline 97
7.4.1 Overview 97
7.4.2 Pipeline by Phase 97
7.5 Most Promising Molecules 98
7.5.1 Uplyso 98
7.5.2 Genz-112638 99
7.5.3 Amigal 101
8 Neurometabolic Disorders Market to 2017- Competitive Landscape 103
8.1 Overview 103
8.2 Company Profiles 105
8.2.1 Genzyme Corporation 105
8.2.2 Shire 113
8.2.3 BioMarin Pharmaceutical Inc. 120
8.2.4 Actelion 124
9 Neurometabolic Disorders Market to 2017 - Strategic Consolidations 128
9.1 Overview 128
9.1.1 Sanofi S.A. Completes Acquisition of Genzyme 129
9.1.2 Pfizer Enters into a Licensing Agreement with Protalix Biotherapeutics 130
9.1.3 GlaxoSmithKline Enters into Licensing Agreement with Amicus Therapeutics for Amigal 130
9.1.4 Amicus Therapeutics Terminates Licensing Agreement with Shire 131
9.2 Deals by Geography 131
9.3 Deals by Licensing Type 132
9.4 Deals by Value 133
9.5 Deals by Phase 134
9.5.1 NDA Filed 134
9.5.2 Phase III 134
10 Neurometabolic Disorders Market to 2017 - Appendix 135
10.1 Market Definitions 135
10.2 Abbreviations 135
10.3 Research Methodology 136
10.3.1 Coverage 136
10.3.2 Secondary Research 137
10.3.3 Primary Research 137
10.4 Therapeutic Landscape 138
10.4.2 Market Size by Geography 140
10.5 Geographical Landscape 141
10.6 Pipeline Analysis 141
10.7 Competitive Landscape 141
10.7.1 Expert Panel Validation 141
10.8 Contact Us 141
10.9 Disclaimer 141
10.10 Sources 142
1.1 List of Tables
Table 1: Neurometabolic Disorders Market to 2017, Global, Revenue ($m), 2002-2010 15
Table 2: Neurometabolic Disorders Market to 2017, Global, Revenue Forecasts ($m), 2010-2017 15
Table 3: Neurometabolic Disorders Market to 2017, Global, Annual Cost of Therapy ($), 2002-2010 16
Table 4: Neurometabolic Disorders Market to 2017, Global, Annual Cost of Therapy ($), 2010-2017 16
Table 5: Neurometabolic Disorders Market to 2017, Global, Treatment Usage Pattern, 2002-2010 17
Table 6: Neurometabolic Disorders Market to 2017, Global, Treatment Usage Pattern, 2010-2017 18
Table 7: Neurometabolic Disorders Market to 2017, Global, Revenue, By Geography ($m), 2002-2010 20
Table 8: Neurometabolic Disorders Market to 2017, Global, Revenue Forecasts, By Geography ($m), 2010-2017 21
Table 9: Neurometabolic Disorders Market to 2017, The US, Revenue ($m), 2002-2010 22
Table 10: Neurometabolic Disorders Market to 2017, The US, Revenue Forecasts ($m), 2010-2017 22
Table 11: Neurometabolic Disorders Market to 2017, The US, Annual Cost of Therapy ($), 2002-2010 23
Table 12: Neurometabolic Disorders Market to 2017, The US, Annual Cost of Therapy ($), 2010-2017 24
Table 13: Neurometabolic Disorders Market to 2017, The US, Treatment Usage Pattern, 2002-2010 25
Table 14: Neurometabolic Disorders Market to 2017, The US, Treatment Usage Pattern, 2010-2017 25
Table 15: Neurometabolic Disorders Market to 2017, Top Five Countries of Europe, Revenue ($m) 2002-2010 27
Table 16: Neurometabolic Disorders Market to 2017, Top Five Countries of Europe, Revenue Forecasts ($m), 2010-2017 27
Table 17: Neurometabolic Disorders Market to 2017, Top Five Countries of Europe, Annual Cost of Therapy ($), 2002-2010 28
Table 18: Neurometabolic Disorders Market to 2017, Top Five Countries of Europe, Annual Cost of Therapy ($), 2010-2017 28
Table 19: Neurometabolic Disorders Market to 2017, Top Five Countries of Europe, Treatment Usage Pattern, 2002-2010 29
Table 20: Neurometabolic Disorders Market to 2017, Top Five Countries of Europe, Treatment Usage Pattern, 2010-2017 30
Table 21: Neurometabolic Disorders Market to 2017, Japan, Revenue ($m), 2002-2010 31
Table 22: Neurometabolic Disorders Market to 2017, Japan, Revenue Forecasts ($m), 2010-2017 32
Table 23: Neurometabolic Disorders Market to 2017, Japan, Annual Cost of Therapy ($), 2002-2010 32
Table 24: Neurometabolic Disorders Market to 2017, Japan, Annual Cost of Therapy ($), 2010-2017 33
Table 25: Neurometabolic Disorders Market to 2017, Japan, Treatment Usage Pattern, 2002-2010 34
Table 26: Neurometabolic Disorders Market to 2017, Japan, Treatment Usage Pattern, 2010-2017 34
Table 27: Neurometabolic Disorders Market to 2017, Global, Gaucher's Disease, Revenue ($m), 2002-2010 36
Table 28: Neurometabolic Disorders Market to 2017, Global, Gaucher's Disease, Revenue Forecasts ($m), 2010-2017 36
Table 29: Neurometabolic Disorders Market to 2017, Global, Gaucher's Disease, Revenue, By Geography ($m), 2002-2010 38
Table 30: Neurometabolic Disorders Market to 2017, Global, Gaucher's Disease, Revenue Forecasts, By Geography ($m), 2010-2017 39
Table 31: Neurometabolic Disorders Market to 2017, Global, Gaucher's Disease, Annual Cost of Therapy ($), 2002-2010 40
Table 32: Neurometabolic Disorders Market to 2017, Global, Gaucher's Disease, Annual Cost of Therapy ($), 2010-2017 40
Table 33: Neurometabolic Disorders Market to 2017, Global, Gaucher's Disease, Treatment Usage Pattern, 2002-2010 41
Table 34: Neurometabolic Disorders Market to 2017, Global, Gaucher's Disease, Treatment Usage Pattern, 2010-2017 42
Table 35: Neurometabolic Disorders Market to 2017, Global, Niemann-Pick Type C, Revenue ($m), 2002-2010 47
Table 36: Neurometabolic Disorders Market to 2017, Global, Niemann-Pick Type C, Revenue Forecasts ($m), 2010-2017 47
Table 37: Neurometabolic Disorders Market to 2017, Global, Niemann-Pick Type C, Revenue, By Geography ($m), 2002-2010 49
Table 38: Neurometabolic Disorders Market to 2017, Global, Niemann-Pick Type C, Revenue Forecasts, By Geography ($m), 2010-2017 49
Table 39: Neurometabolic Disorders Market to 2017, Global, Niemann-Pick Type C, Annual Cost of Therapy ($), 2009-2017 50
Table 40: Neurometabolic Disorders Market to 2017, Global, Niemann-Pick Type C, Treatment Usage Pattern, 2002-2010 51
Table 41: Neurometabolic Disorders Market to 2017, Global, Niemann-Pick Type C, Treatment Usage Pattern, 2010-2017 52
Table 42: Neurometabolic Disorders Market to 2017, Global, Pompe Disease, Revenue ($m), 2002-2010 57
Table 43: Neurometabolic Disorders Market to 2017, Global, Pompe Disease, Revenue Forecasts ($m), 2010-2017 57
Table 44: Neurometabolic Disorders Market to 2017, Global, Pompe Disease, Revenue, By Geography ($m), 2002-2010 59
Table 45: Neurometabolic Disorders Market to 2017, Global, Pompe Disease, Revenue Forecasts, By Geography ($m), 2010-2017 59
Table 46: Neurometabolic Disorders Market to 2017, Global, Pompe Disease, Annual Cost of Therapy ($), 2002-2010 60
Table 47: Neurometabolic Disorders Market to 2017, Global, Pompe Disease, Annual Cost of Therapy ($), 2010-2017 61
Table 48: Neurometabolic Disorders Market to 2017, Global, Pompe Disease, Treatment Usage Pattern, 2002-2010 62
Table 49: Neurometabolic Disorders Market to 2017, Global, Pompe Disease, Treatment Usage Pattern, 2010-2017 62
Table 50: Neurometabolic Disorders Market to 2017, Global, Fabry Disease, Revenue ($m), 2002-2010 66
Table 51: Neurometabolic Disorders Market to 2017, Global, Fabry Disease, Revenue Forecasts ($m), 2010-2017 66
Table 52: Neurometabolic Disorders Market to 2017, Global, Fabry Disease, Revenue, By Geography ($m), 2002-2010 68
Table 53: Neurometabolic Disorders Market to 2017, Global, Fabry Disease, Revenue Forecasts, By Geography ($m), 2010-2017 68
Table 54: Neurometabolic Disorders Market to 2017, Global, Fabry Disease, Annual Cost of Therapy ($), 2002-2010 69
Table 55: Neurometabolic Disorders Market to 2017, Global, Fabry Disease, Annual Cost of Therapy ($), 2010-2017 69
Table 56: Neurometabolic Disorders Market to 2017, Global, Fabry Disease, Treatment Usage Pattern, 2002-2010 70
Table 57: Neurometabolic Disorders Market to 2017, Global, Fabry Disease, Treatment Usage Pattern, 2010-2017 71
Table 58: Neurometabolic Disorders Market to 2017, Global, Mucopolysaccharidosis VI, Revenue ($m), 2002-2010 74
Table 59: Neurometabolic Disorders Market to 2017, Global, Mucopolysaccharidosis VI, Revenue Forecasts ($m), 2010-2017 74
Table 60: Neurometabolic Disorders Market to 2017, Global, Mucopolysaccharidosis VI, Revenue, By Geography ($m), 2002-2010 75
Table 61: Neurometabolic Disorders Market to 2017, Global, Mucopolysaccharidosis VI, Revenue Forecasts, By Geography ($m), 2010-2017 76
Table 62: Neurometabolic Disorders Market to 2017, Global, Mucopolysaccharidosis VI, Annual Cost of Therapy ($), 2002-2010 76
Table 63: Neurometabolic Disorders Market to 2017, Global, Mucopolysaccharidosis VI, Annual Cost of Therapy ($), 2010-2017 77
Table 64: Neurometabolic Disorders Market to 2017, Global, Mucopolysaccharidosis VI, Treatment Usage Pattern, 2002-2010 77
Table 65: Neurometabolic Disorders Market to 2017, Global, Mucopolysaccharidosis VI, Treatment Usage Pattern, 2010-2017 78
Table 66: Neurometabolic Disorders Market to 2017, Global, Major Marketed Products, 2010 82
Table 67: Neurometabolic Disorders Market to 2017, Global, Gaucher's Disease, Pipeline by Phase, 2011 94
Table 68: Neurometabolic Disorders Market to 2017, Global, Niemann-Pick Type C, Pipeline by Phase, 2011 95
Table 69: Neurometabolic Disorders Market to 2017, Global, Pompe Disease, Pipeline by Phase, 2011 96
Table 70: Neurometabolic Disorders Market to 2017, Global, Fabry Disease, Pipeline by Phase, 2011 97
Table 71: Neurometabolic Disorders Market to 2017, Global, Pipeline, Most Promising Molecules, 2011 98
Table 72: Neurometabolic Disorders Market to 2017, Global, Major Marketed Products, 2010 104
Table 73: Neurometabolic Disorders Market to 2017, Global, Genzyme Corporation, Major Deals, 2004-2011 106
Table 74: Neurometabolic Disorders Market to 2017, Global, Shire plc, Major Deals, 2004-2011 114
Table 75: Neurometabolic Disorders Market to 2017, Global, BioMarin Pharmaceutical Inc., Major Deals, 2004-2011 122
Table 76: Neurometabolic Disorders Market to 2017, Global, Actelion Ltd., Major Deals, 2004-2011 126
Table 77: Neurometabolic Disorders Market to 2017, Global, Comparison of Therapy Areas under Drug Development and Research, 2011 129
Table 78: Neurometabolic Disorders Market to 2017, Global, Genzyme Corporation, Late-stage Pipeline, 2011 130
1.2 List of Figures
Figure 1: Neurometabolic Disorders Market to 2017, Global, Revenue Forecasts ($m), 2002-2017 15
Figure 2: Neurometabolic Disorders Market to 2017, Global, Annual Cost of Therapy ($), 2002-2017 16
Figure 3: Neurometabolic Disorders Market to 2017, Global, Treatment Usage Pattern, 2002-2017 17
Figure 4: Neurometabolic Disorders Market to 2017, Global, Revenue Forecasts, By Geography ($m), 2002-2017 20
Figure 5: Neurometabolic Disorders Market to 2017, The US, Revenue Forecasts ($m), 2002-2017 22
Figure 6: Neurometabolic Disorders Market to 2017, The US, Annual Cost of Therapy ($), 2002-2017 23
Figure 7: Neurometabolic Disorders Market to 2017, The US, Treatment Usage Pattern, 2002-2017 24
Figure 8: Neurometabolic Disorders Market to 2017, Top Five Countries of Europe, Revenue Forecasts ($m), 2002-2017 27
Figure 9: Neurometabolic Disorders Market to 2017, Top Five Countries of Europe, Annual Cost of Therapy ($), 2002-2017 28
Figure 10: Neurometabolic Disorders Market to 2017, Top Five Countries of Europe, Treatment Usage Pattern, 2002-2017 29
Figure 11: Neurometabolic Disorders Market to 2017, Japan, Revenue Forecasts ($m), 2002-2017 31
Figure 12: Neurometabolic Disorders Market to 2017, Japan, Annual Cost of Therapy ($), 2002-2017 32
Figure 13: Neurometabolic Disorders Market to 2017, Japan, Treatment Usage Pattern, 2002-2017 33
Figure 14: Neurometabolic Disorders Market to 2017, Global, Gaucher's Disease, Revenue Forecasts ($m), 2002-2017 36
Figure 15: Neurometabolic Disorders Market to 2017, Global, Gaucher's Disease, Revenue Forecasts, By Geography ($m), 2002-2017 38
Figure 16: Neurometabolic Disorders Market to 2017, Global, Gaucher's Disease, Annual Cost of Therapy ($), 2002-2017 40
Figure 17: Neurometabolic Disorders Market to 2017, Global, Gaucher's Disease, Treatment Usage Pattern, 2002-2017 41
Figure 18: Neurometabolic Disorders Market to 2017, Gaucher's Disease, Treatment Algorithm, 2011 43
Figure 19: Neurometabolic Disorders Market to 2017, Gaucher's Disease, Drivers and Restraints, 2011 44
Figure 20: Neurometabolic Disorders Market to 2017, Global, Niemann-Pick Type C, Revenue Forecasts ($m), 2009-2017 47
Figure 21: Neurometabolic Disorders Market to 2017, Global, Niemann-Pick Type C, Revenue Forecasts, By Geography ($m), 2009-2017 49
Figure 22: Neurometabolic Disorders Market to 2017, Global, Niemann-Pick Type C, Annual Cost of Therapy ($), 2009-2017 50
Figure 23: Neurometabolic Disorders Market to 2017, Global, Niemann-Pick Type C, Treatment Usage Pattern, 2002-2017 51
Figure 24: Neurometabolic Disorders Market to 2017, Niemann-Pick Type C, Treatment Algorithm, 2011 53
Figure 25: Neurometabolic Disorders Market to 2017, Niemann-Pick Type C, Drivers and Restraints, 2011 54
Figure 26: Neurometabolic Disorders Market to 2017, Global, Pompe Disease, Revenue Forecasts ($m), 2006-2017 56
Figure 27: Neurometabolic Disorders Market to 2017, Global, Pompe Disease, Revenue Forecasts, By Geography ($m), 2006-2017 58
Figure 28: Neurometabolic Disorders Market to 2017, Global, Pompe Disease, Annual Cost of Therapy ($), 2006-2017 60
Figure 29: Neurometabolic Disorders Market to 2017, Global, Pompe Disease, Treatment Usage Pattern, 2002-2017 61
Figure 30: Neurometabolic Disorders Market to 2017, Pompe Disease, Treatment Algorithm, 2011 63
Figure 31: Neurometabolic Disorders Market to 2017, Pompe Disease, Drivers and Restraints, 2011 64
Figure 32: Neurometabolic Disorders Market to 2017, Global, Fabry Disease, Revenue Forecasts ($m), 2002-2017 66
Figure 33: Neurometabolic Disorders Market to 2017, Global, Fabry Disease, Revenue Forecasts, By Geography ($m), 2002-2017 67
Figure 34: Neurometabolic Disorders Market to 2017, Global, Fabry Disease, Annual Cost of Therapy ($), 2002-2017 69
Figure 35: Neurometabolic Disorders Market to 2017, Global, Fabry Disease, Treatment Usage Pattern, 2002-2017 70
Figure 36: Neurometabolic Disorders Market to 2017, Fabry Disease, Drivers and Restraints, 2011 72
Figure 37: Neurometabolic Disorders Market to 2017, Global, Mucopolysaccharidosis VI, Revenue Forecasts ($m), 2005-2017 74
Figure 38: Neurometabolic Disorders Market to 2017, Global, Mucopolysaccharidosis VI, Revenue Forecasts, By Geography ($m), 2005-2017 75
Figure 39: Neurometabolic Disorders Market to 2017, Global, Mucopolysaccharidosis VI, Annual Cost of Therapy ($), 2005-2017 76
Figure 40: Neurometabolic Disorders Market to 2017, Global, Mucopolysaccharidosis VI, Treatment Usage Pattern, 2002-2017 77
Figure 41: Neurometabolic Disorders Market to 2017, Mucopolysaccharidosis VI, Treatment Algorithm, 2011 79
Figure 42: Neurometabolic Disorders Market to 2017, Mucopolysaccharidosis VI, Drivers and Restraints, 2011 80
Figure 43: Neurometabolic Disorders Market to 2017, Global, Pipeline by Phase, 2011 92
Figure 44: Neurometabolic Disorders Market to 2017, Global, Pipeline by Indication, 2011 93
Figure 45: Neurometabolic Disorders Market to 2017, Global, Gaucher's Disease, Pipeline by Phase, 2011 94
Figure 46: Neurometabolic Disorders Market to 2017, Global, Pompe Disease, Pipeline by Phase, 2011 96
Figure 47: Neurometabolic Disorders Market to 2017, Global, Fabry Disease, Pipeline by Phase, 2011 97
Figure 48: Neurometabolic Disorders Market to 2017, Global, Competitive Landscape (%), 2010 103
Figure 49: Neurometabolic Disorders Market to 2017, Global, Competitive Analysis of Top Four Players, Market Share and CAGR (%), 2008-2010 104
Figure 50: Neurometabolic Disorders Market to 2017, Global, Genzyme Corporation, SWOT Analysis, 2010 105
Figure 51: Neurometabolic Disorders Market to 2017, Global, Shire plc, SWOT Analysis, 2010 113
Figure 52: Neurometabolic Disorders Market to 2017, Global, BioMarin Pharmaceutical Inc., SWOT Analysis, 2010 121
Figure 53: Neurometabolic Disorders Market to 2017, Global, Actelion Ltd., SWOT Analysis, 2010 125
Figure 54: Neurometabolic Disorders Market to 2017, Global, Deals by Indication (%), 2011 128
Figure 55: Neurometabolic Disorders Market to 2017, Global, Deals by Geography (%), 2004-2011 131
Figure 56: Neurometabolic Disorders Market to 2017, Global, Deals by Type (%), 2004-2011 132
Figure 57: Neurometabolic Disorders Market to 2017, Global, Deals by Value (%), 2004-2011 133
Figure 58: Neurometabolic Disorders Market to 2017, Global, Deals by Phase (%), 2004-2011 134
Figure 59: GBI Research Market Forecasting Model 140
Companies mentioned
Genzyme Corporation
Shire
BioMarin Pharmaceutical Inc.
Actelion
To order this report:
Pathology Industry: Neurometabolic Disorders Market to 2017 - Novel Therapies for Rare Diseases such as Gaucher's and Niemann-Pick Poised to Supersede Existing Therapies
Check our Industry Analysis and Insights
CONTACT:
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article